Avalo Therapeutics initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $48 price target The LOTUS Phase 2 trial readout due around May or June “will likely dictate the fate of Avalo,” says the analyst, who acknowledges that this is “a high-risk stock call” but skews “toward the bull camp” after analyzing transcriptomic, clinical and pharmacology data.